{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-23-000007","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.807066+00:00","generated_at":"2026-06-19T04:07:36.593287+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"United Therapeutics reports record 2022 revenue of $1.94B, up 15% YoY; Q4 EPS $2.67","bullets":["Full year total revenues $1.94B, up 15% YoY; net income $727.3M ($15.00 diluted EPS).","Q4 revenues $491.5M, net income $132.1M ($2.67 diluted EPS).","Tyvaso net product sales $873M for 2022, up 44% YoY driven by Tyvaso DPI launch and PH-ILD expansion.","Treprostinil product sales grew 19% in 2022; company targets $4B revenue run rate by end of 2025.","Unituxin sales declined 10% to $182.9M; Adcirca down 26% due to generic competition."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-23-000007","json":"https://secwatch.observer/filing/0001082554-23-000007.json","markdown":"https://secwatch.observer/filing/0001082554-23-000007.md","text":"https://secwatch.observer/filing/0001082554-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/0001082554-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/uthr-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T04:07:36.593287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"163e5aba8b3bf7cbe6ab298057afbdd68ae41873","claim":"UNITED THERAPEUTICS Corp reported Three Months Ended December 31, 2022 results: revenue $ 491.5, net income $ 132.1, EPS $ 2.67.","evidence_excerpt":"Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenues $ 491.5 $ 415.2 $ 1,936.3 $ 1,685.5 Net income $ 132.1 $ 112.2 $ 727.3 $ 475.8 Net income, per basic share $ 2.88 $ 2.49 $ 15.98 $ 10.60 Net income, per diluted share $ 2.67 $ 2.35 $ 15.00 $ 10.06","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/0001082554-23-000007-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Three Months Ended December 31, 2022"},{"label":"Revenue","value":"$ 491.5"},{"label":"Net income","value":"$ 132.1"},{"label":"EPS","value":"$ 2.67"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"96020c9398046aff9327ca7e79dd0100c1f8e59c","claim":"UNITED THERAPEUTICS Corp reported Year Ended December 31, 2022 results: revenue $ 1,936.3, net income $ 727.3, EPS $ 15.00.","evidence_excerpt":"Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenues $ 491.5 $ 415.2 $ 1,936.3 $ 1,685.5 Net income $ 132.1 $ 112.2 $ 727.3 $ 475.8 Net income, per basic share $ 2.88 $ 2.49 $ 15.98 $ 10.60 Net income, per diluted share $ 2.67 $ 2.35 $ 15.00 $ 10.06","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/0001082554-23-000007-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Year Ended December 31, 2022"},{"label":"Revenue","value":"$ 1,936.3"},{"label":"Net income","value":"$ 727.3"},{"label":"EPS","value":"$ 15.00"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}